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score of each individual pa-
tient with non-small cell lung 
cancers (NSCLC) to predict 
survival. It is our hope that the 
risk score can be used for 
more accurate patient stratifi-
cation for surgical and chemo-
therapeutic treatment in com-
bination with TNM stage in the 
patient with NSCLC. In another 
study, our cancer gene profil-
ing in 932 FFPE tissues with 
NSCLC revealed 1% of acti-
vating somatic mutations in 
JAK2 and 6.7% of germline 
mutations in JAK3, and further 
indicated that both gene mu-
tations could confer sensitivity 
to both JAK inhibitors and anti-
PD1 immunotherapy.  Says Dr, 
Ye, “I am very happy to join 
the Genomic Core lab in the 
Department of Pathology, and 
I am thinking of pursuing 
translational research projects 
in oncology, virology and oth-
ers using integrated genomic 
and proteomic analyses.” 
The Department of Pathology is 
proud to introduce the latest 
addition to our faculty, Dr. Fei 
Ye.  Dr. Ye’s research has mainly 
focused on understanding the 
perturbation of signaling path-
ways and signaling networks at 
genomic and proteomic level in 
several cancers, including lung 
cancer, gastric cancer, etc. To 
meet the demand of rapid tran-
sition from genomics to prote-
omics, Dr. Ye and her mentor 
Dr. Zhang developed an innova-
tive Proteomic Pathway Array 
(PPA) in 2005 (Cell Div. 2009 
Oct 28;4:20), which can be used 
to screen protein expression 
and activation of the signaling 
pathways (i.e. phosphorylation) 
in different diseases including 
cancer. The significant ad-
vantages of this technology 
over other proteomic arrays 
and genomic level include an 
improved sensitivity and speci-
ficity to detect low abundance 
proteins and specific proteins, 
and a high recovery rate of 
differentially expressed  proteins 
and phosphoproteins. It provides 
a better understanding of dis-
ease at the signaling pathway 
and network level. Using this 
novel PPA, we have identified 
various protein biomarkers for 
molecular classification and stag-
ing of various cancers and guid-
ing the targeted therapy and 
prognosis. For example, we gen-
erated a risk score model using 
five protein biomarkers (Factor 
XIII B, TFIIH p89, ADAM8, COX-2 
and CUL-1) identified by PPA to 
predict lymph node metastasis 
and prognosis in gastric cancer. 
One more example, the four 
proteins (CDK4, HSP90, p-CREB 
and CREB) were identified by the 
PPA, which generated the risk 
Spotlight on Research:  Welcome Dr. Ye! 
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NYMC has a new research microscope! 
Thanks to Dr. Paul Lucas and ASC Biosciences, the new Nikon TIE-PFS Mo-
torized inverted Microscope System will be housed in BSB 434. It is capable 
of bright field, phase, and fluorescence microscopy.  Fluorescence is DAPI, 
GFP, Rhodamine, and Cy5.  Objectives are 4x, 10x, 20x, and 40x.  The mi-
croscope comes with NIS software.  
Please contact Anne Sollas, anne_sallas@nymc.edu,  for more information. 
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Study Sponsor: Regeneron 
“Blood and Fresh Tumor Tissue Acquisition for Patient Derived Xenograft (PDX) Studies” 
The purpose of this study is to determine genetic contribution to the development of solid 
malignant tumors through genomic sequencing. 
 
Study Sponsor: Regeneron 
“Healthy Subject Blood For Research” 
The purpose of this study is to collect blood from healthy subjects for use in research stud-
ies in order to calibrate research laboratory equipment, set normal ranges for values meas-
ured in research laboratory assays, and determine whether blood from healthy subjects can 
provide information about the abnormalities underlying certain diseases. 
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